3-酰胺苯甲酰胺衍生物的合成及体外抗肿瘤活性的初步研究
Synthesis and anti- tumor activity research of a novel series of 3- amidebenzamide derivatives
作者：李博;邵薇;何谷;成丽;郭丽;
Author：
收稿日期： 年卷（期）页码：2014,29(01):-1-4
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：3-氨基苯甲酰胺衍生物;合成;抗肿瘤
Key words：
基金项目：国家自然科学基金资助项目(批准号:81001357)
中文摘要
目的合成一类新型3-酰胺苯甲酰胺衍生物并研究其体外抗肿瘤活性。方法以2-甲基-5-氨基苯甲酸和2-氯-5-氨基苯甲酸等为起始原料,经过氨基Boc保护、羧基形成酰胺、脱保护基、酰化等反应得到目标化合物;采用MTT法在前列腺癌细胞PC-3、人卵巢癌细胞SKOV-3、人结直肠癌细胞HCT116、人肝癌细胞Hep-G2、人恶性黑色素瘤细胞A375、人肺癌细胞A549和慢性髓细胞性白血病细胞K562等细胞株上进行了体外抗肿瘤活性的测试。结果与结论合成了9个新型化合物,并经1HNMR、MS确证了化学结构。初步的体外抗肿瘤活性显示:化合物Ⅳh和Ⅳi显示出对白血病细胞有较好的活性。
英文摘要
[1]唐军,傅大煦.靶向小分子创新药物[J].现代生物医学进展,2010,20:3997-4000.
[2]Wilhelm S,Carter C,Lynch M,et al.Discovery and development of sorafenib:A multikinase inhibitor for treating cancer[J].Nat Rev Drug Discov,2006,5(10):835-844.
[3]Guida T,Anaganti S,Provitera L,et al.Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants[J].Clin Cancer Res,2007,13(11):3363-3369.
[4]Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res,2004,64(19):7099-7109.
[5]Adnane L,Trail PA,Taylor I,et al.Sorafenib(BAY 43-9006,Nexavar),a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature[J].Methods Enzymol,2006,407:597-612.
[6]David AS,Brian MA,Geraldine AB,et al.Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer[J].Bioorg Med Chem Lett,2008,18(17):4794-4797.
[7]Lyne PD,Aquila B,Cook DJ,et al.Identification of amidoheteroaryls as potent inhibitors of mutant(V600E)B-Raf kinase with in vivo activity[J].Bioorg Med Chem Lett,2009,19(3):1026-1029.
[8]Salah MS,Robert TD,David SA,et al.2-Substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones.A new class of antitumor agent[J].J Med Chem,1993,36(6):765-770.
【关闭】
